March 2015 March 2015
New Product - Femoston 1/10
Femoston 1/10 (oestradiol and dydrogesterone) hormone replacement therapy is indicated in oestrogen deficiency associated with natural or artificial menopause in women with intact uteri; prevention of postmenopausal bone mineral density loss in women at high risk of osteoporosis and future fracture where nonoestrogen products are contraindicated or not tolerated. Femoston 1/10 is contraindicated in the following conditions: hysterectomy; untreated endometrial hyperplasia; oestrogen dependent neoplasia (e.g. breast, endometrium), progestogen dependent neoplasm (including suspected); active, chronic or history of liver disease if liver function tests are still abnormal; cerebrovascular accident or history associated with oestrogen use; venous thromboembolism (VTE); idiopathic VTE history; thrombophilic disorder including protein C, S or antithrombin deficiency; active, recent arterial thromboembolic disease, e.g. angina, myocardial infarction; undiagnosed abnormal genitourinary bleeding; porphyria; pregnancy (included suspected) and lactation. Femoston 1/10 is available as immediate release tablets containing 14 tablets (oestradiol 1 mg) + 14 tablets (oestradiol 1 mg/ dydrogesterone 10 mg) in blister strips.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au